Chloroquine
| Property | Information |
|---|---|
| Drug Name | Chloroquine and Hydroxychloroquine |
| FDA Approval | No (for glioblastoma treatment) |
| Used for | Glioblastoma, in combination with traditional chemotherapy agents |
| Clinical Trial Phase | Reviewed in recent meta-analyses and studies |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Generally well-tolerated; specific studies noted minimal impact on adverse event incidence |
| OS without | BCNU alone: median survival of 11 months |
| OS with | Chloroquine with BCNU: median survival significantly improved to 25-33 months; recent meta-analysis supports decreased mortality and improved survival time in glioblastoma patients |
| PFS without | Not specified in the recent analysis |
| PFS with | Not directly specified; chloroquine shown to induce remission rates without increasing adverse events significantly |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Recent studies highlight Chloroquine's potential in glioblastoma treatment, significantly improving survival rates when combined with chemotherapy. Chloroquine acts as an autophagy inhibitor, potentially enhancing chemotherapy's effectiveness by inhibiting a survival mechanism in cancer cells. Hydroxychloroquine's efficacy at the maximum tolerated dose has not shown improvement in survival, suggesting Chloroquine as the more promising agent for future clinical trials, especially considering tumor genetic profiles such as EGFR status.
Links: * [Chloroquine Supplementation for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies - PubMed](https://pubmed.ncbi.nlm.nih.gov/36409625)
- [Chloroquine in Cancer Therapy: A Double-Edged Sword of Autophagy - AACR Journals](https://aacrjournals.org/cancerres/article/73/1/3/584147/Chloroquine-in-Cancer-Therapy-A-Double-Edged-Sword)
From Ben Williams Book: Not specified
